PTJ
AKBA icon

Paul Tudor Jones’s Akebia Therapeutics AKBA Stock Holding History

Paul Tudor Jones’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,900
Closed -$15.2K – 3487
2026
Q1 		$15.2K Hold
10,900
– – ﹤0.01% 3506
2025
Q4 		$17.5K Buy
+10,900
New +$22.8K ﹤0.01% 3417

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Paul Tudor Jones's AKBA Position: Q4 2024 in Review

Paul Tudor Jones sold out of Akebia Therapeutics (AKBA) in Q4 2024, closing a stake of 142,274 shares — an estimated $188K sold.

Paul Tudor Jones first reported a position in AKBA in Q1 2016 and held it in 22 quarters. The position peaked at $605K in Q1 2021. 121 funds tracked by Wall St. Rank hold AKBA as of Q4 2024.

  • Paul Tudor Jones reported no remaining Akebia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 142,274 Akebia Therapeutics shares in Q4 2024, an estimated $188K.
  • Paul Tudor Jones first reported a position in Akebia Therapeutics in Q1 2016 and held it in 22 quarters.
  • Paul Tudor Jones's Akebia Therapeutics position peaked at $605K in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.